Year archive

Medivir — 2014 filings

All 76 regulatory filings released by Medivir (MVIR) in 2014, sourced directly from the official regulator.

76 Filings

2014 Period

2014 filings (76)

Filing	Released	Lang
MIV-802 has been selected as a candidate drug and enters non-clinical development for the treatment of hepatitis C infection Regulatory Filings	2014-12-22	English
MIV-802 har valts som läkemedelskandidat för behandling av hepatit C-infektion och går in i preklinisk utvecklingsfas Regulatory Filings	2014-12-22	Swedish
Major Shareholding Notification 2014 Major Shareholding Notification	2014-11-25	English
Beslut vid extra bolagsstämma i Medivir den 20 november 2014 Share Issue/Capital Change	2014-11-20	Swedish
Resolutions at the extraordinary general meeting in Medivir on 20 November 2014 Share Issue/Capital Change	2014-11-20	English
Interim / Quarterly Report 2014 Interim / Quarterly Report 9M 2014	2014-11-20	Swedish
Interim / Quarterly Report 2014 Interim / Quarterly Report 9M 2014	2014-11-20	English
Olysio® gains additional FDA approval as all-oral treatment in combination with sofosbuvir for treatment of hepatitis C infection Earnings Release FY 2014	2014-11-06	English
Ytterligare godkännande från den amerikanska läkemedelsmyndigheten för hepatit C-behandling med Olysio® i kombination med sofosbuvir Regulatory Filings	2014-11-06	Swedish
Medivir and county councils conclude agreement on Olysio®-based treatment for hepatitis C Regulatory Filings	2014-10-30	English
Medivir och landstingen ingår överenskommelse kring hepatit C-behandling med Olysio® Regulatory Filings	2014-10-30	Swedish
Medivir Nomination Committee appointed Board/Management Information	2014-10-28	English
Medivirs valberedning tillsatt Board/Management Information	2014-10-28	Swedish
Kallelse till extra bolagsstämma i Medivir AB (publ) AGM Information	2014-10-23	Swedish
Notice of extraordinary general meeting of Medivir AB (publ) AGM Information	2014-10-23	English
Optimization of capital structure Capital/Financing Update	2014-10-16	English
Optimering av kapitalstruktur Notice of Dividend Amount	2014-10-16	Swedish
Stable sales for OLYSIO during the third quarter 2014 Earnings Release Q3 2014	2014-10-14	English
Stabil försäljning för OLYSIO under tredje kvartalet 2014 Earnings Release Q3 2014	2014-10-14	Swedish
Start av fas II-studien IMPACT för utvärdering av Simeprevir i kombination med Sofosbuvir och Daclatasvir vid behandling av hepatit C- patienter Regulatory Filings	2014-10-10	Swedish
Phase II IMPACT study initiated to evaluate Simeprevir in combination with Sofosbuvir and Daclatasvir to treat genotype 1 and 4 hepatitis C patients Regulatory Filings	2014-10-10	English
Medivir presenterar data från Cathepsin S-hämmarprogrammet, inklusive MIV-247, för behandling av neuropatisk smärta vid 15th World Congress on Pain Regulatory Filings	2014-10-09	Swedish
Medivir to present data from its Cathepsin S inhibitor program including MIV-247 for neuropathic pain, at the 15th World Congress on Pain Regulatory Filings	2014-10-09	English
Medivir Capital Markets Meeting on 16 October 2014 Investor Presentation	2014-10-07	English
Medivir anordnar kapitalmarknadsmöte den 16 oktober 2014 Report Publication Announcement	2014-10-07	Swedish
Major Shareholding Notification 2014 Major Shareholding Notification	2014-09-18	English
Earnings Release 2014 Earnings Release H1 2014	2014-08-21	Swedish
Interim / Quarterly Report 2014 Interim / Quarterly Report H1 2014	2014-08-21	English
Niklas Prager appointed new President and CEO of Medivir Board/Management Information	2014-08-11	English
Niklas Prager utsedd till ny verkställande direktör för Medivir Board/Management Information	2014-08-11	Swedish
Medivir inlicensierar RS-virusprogram från Boehringer Ingelheim Regulatory Filings	2014-08-04	Swedish
Medivir licenses Respiratory Syncytial Virus drug program from Boehringer Ingelheim Regulatory Filings	2014-08-04	English
Phase II COSMOS study results published in The Lancet on World Hepatitis Day Regulatory Filings	2014-07-28	English
Fas II-data från COSMOS-studien publicerade i The Lancet i samband med Världshepatitdagen Regulatory Filings	2014-07-28	Swedish
U.S. FDA has granted Priority Review for OLYSIO® in combination with sofosbuvir supplementary New Drug Application Regulatory Filings	2014-07-15	English
FDA har beviljat prioriterad granskning av kompletterande registreringsansökan (sNDA) för behandling med OLYSIO® i kombination med sofosbuvir Regulatory Filings	2014-07-15	Swedish
OLYSIO™ available soon in all Nordic countries for the treatment of adults with hepatitis C genotype 1 and 4 infection Regulatory Filings	2014-06-10	English
OLYSIO™ snart tillgänglig i samtliga nordiska länder för behandling av vuxna patienter med hepatit C av genotyp 1 och 4 Earnings Release H2 2014	2014-06-10	Swedish
Major Shareholding Notification 2014 Major Shareholding Notification	2014-05-21	English
Simeprevir approved in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection Regulatory Filings	2014-05-16	English
Simeprevir har godkänts inom EU för behandling av vuxna patienter med hepatit C av genotyp 1 och 4 Regulatory Filings	2014-05-16	Swedish
Major Shareholding Notification 2014 Major Shareholding Notification	2014-05-14	English
Resolutions at the annual general meetings in Medivir on 8 May 2014 AGM Information	2014-05-08	English
Beslut vid årsstämma i Medivir den 8 maj 2014 AGM Information	2014-05-08	Swedish
Earnings Release 2014 Earnings Release Q1 2014	2014-05-08	Swedish
Interim / Quarterly Report 2014 Interim / Quarterly Report Q1 2014	2014-05-08	English
A supplemental New Drug Application has been submitted to the U.S. FDA for Simeprevir in combination with Sofosbuvir Regulatory Filings	2014-05-07	English
Kompletterande registreringsansökan (sNDA) för Simeprevir i kombination med Sofosbuvir har lämnats in till den amerikanska läkemedelsmyndigheten FDA Regulatory Filings	2014-05-07	Swedish
Adasuve will now be launched in Sweden, Norway, Finland and Denmark Regulatory Filings	2014-04-30	English
Adasuve lanseras nu i Sverige, Norge, Finland och Danmark Regulatory Filings	2014-04-30	Swedish
Positivt marknadsmottagande för Simeprevir under första kvartalet 2014 Earnings Release Q1 2014	2014-04-15	Swedish
Good market uptake for Simeprevir during the first quarter 2014 Earnings Release Q1 2014	2014-04-15	English
Final data from the phase II COSMOS study with Simeprevir in combination with Sofosbuvir presented at EASL Regulatory Filings	2014-04-12	English
Finala data från fas II-studien COSMOS med Simeprevir i kombination med Sofosbuvir har presenterats vid EASL Regulatory Filings	2014-04-12	Swedish
Annual Report 2013 Annual Report FY 2013	2014-04-07	Swedish
Annual Report 2013 Annual Report FY 2013	2014-04-07	English
Notice of Annual General Meeting of Medivir AB (publ) AGM Information	2014-04-07	English
Kallelse till årsstämma i Medivir AB (publ) AGM Information	2014-04-07	Swedish
Declaration of Voting Results & Voting Rights Announcements 2014 Declaration of Voting Results & Voting Rights Announcements	2014-04-03	English
Two phase III trials evaluating once-daily Simeprevir and Sofosbuvir in hepatitis C infected patients have been initiated Regulatory Filings	2014-04-02	English
Två fas III-studier har startat som utvärderar behandling av hepatit C-patienter med Simeprevir och Sofosbuvir en gång om dagen Regulatory Filings	2014-04-02	Swedish
New Simeprevir data will be presented at The International Liver Congress 2014 of the European Association for the Study of the Liver, (EASL) Regulatory Filings	2014-03-24	English
Nya data för Simeprevir kommer att presenteras vid EASL:s ”International Liver Congress”, den 9-13 april i London Regulatory Filings	2014-03-24	Swedish
Simeprevir erhåller positivt utlåtande från den europeiska läkemedelsmyndigheten avseende behandling av vuxna patienter med kronisk hepatit C inom EU Legal Proceedings Report	2014-03-21	Swedish
Simeprevir receives positive CHMP opinion for the treatment of adults with chronic hepatitis C in the European Union Regulatory Filings	2014-03-21	English
Nya resultat från fas III-studier med Simeprevir har presenterats vid The Conference of the Asian Pacific Association for the Study of the Liver Earnings Release FY 2014	2014-03-17	Swedish
New Phase III Data from Once-Daily Simeprevir Presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL) Earnings Release FY 2014	2014-03-17	English
Valberedningens förslag till ny styrelse inför årsstämman 2014 AGM Information	2014-03-14	Swedish
The Nomination Committee’s proposal, with reference to the upcoming 2014 Annual General Meeting, for a new Board of Directors Board/Management Information	2014-03-14	English
SVR12 results from a phase IIa study evaluating Simeprevir and Daclatasvir in Hepatitis C patients of genotype 1 have been presented Regulatory Filings	2014-03-04	English
SVR12-resultat från fas IIa-studie som utvärderar Simeprevir och Daclatasvir i patienter med hepatit C genotyp 1 har presenterats Regulatory Filings	2014-03-04	Swedish
Major Shareholding Notification 2014 Major Shareholding Notification	2014-03-04	English
Earnings Release 2013 Earnings Release FY 2013	2014-02-24	Swedish
Interim / Quarterly Report 2013 Interim / Quarterly Report FY 2013	2014-02-24	English
Interim results (SVR4) from a phase II all-oral combination study of Simeprevir and Samatasvir (IDX719) for the treatment of hepatitis C Regulatory Filings	2014-01-13	English
Interimsresultat (SVR4) från fas II kombinationsstudie med Simeprevir och Samatasvir (IDX719) för behandling av hepatit C Earnings Release FY 2014	2014-01-13	Swedish

Filings by year

2026 19 filings
2025 39 filings
2024 32 filings
2023 33 filings
2022 15 filings
2021 52 filings
2020 28 filings
2019 19 filings
2018 57 filings
2017 52 filings
2016 59 filings
2015 70 filings
2014 76 filings
2013 93 filings
2012 51 filings
2011 79 filings
2010 78 filings
2009 45 filings
2008 40 filings
2007 26 filings